News

Kathryn Golden, SVP Technical Operations & Cell Manufacturing, discusses how our opti-ox technology lends itself to scale through ...

Industrialising human cell manufacturing will unleash the potential of synthetic biology for reproducible research and affordable ...

The piece covers bit.bio's breakthrough in industrialising the consistent manufacture of human cells and how this will transform h...

ioMicroglia™ is set to accelerate research and drug discovery for neurodegenerative disease.

bit.bio launches the first commercially available human iPSC-derived disease models for Parkinson’s disease that carry the PRKN R2...

The piece covers the launch of bit.bio's Custom ioDisease Model Cells at the SynBioBeta conference.

Offering will provide robust, standardised tools for research and drug discovery.

Mark Kotter shares his thoughts in Labiotech on the importance of government support in enabling the UK to become a leading scienc...